ALG.APV-527 by Alligator Bioscience for Solid Tumor: Likelihood of Approval
ALG.APV-527 is under clinical development by Alligator Bioscience and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how ALG.APV-527's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.ALG.APV-527 overviewALG.APV-527 is under development for the treatment of metastatic solid tumors such as colon carcinoma, melanoma, breast cancer, cervical cancer, non-small cell-lung cancer, prostate cancer, endometrial cancer, renal cancer, gastric cancer, colorectal cancer, malignant mesothelioma, malignant pleural mesothelioma, urothelial carcinoma, head and neck cancer, pancreatic cancer, ovarian cancer, throat cancer and gastroesophageal (GE) junction carcinomas. It is based on SLIMCAN concept. The drug candidate is a bi-specific antibody that acts by targeting 4-1BB (CD137), a member of tumor necrosis factor receptor superfamily (TNFRSF) and 5T4 protein. It is developed using ALLIGATOR-GOLD and FIND (Fragment Induced Diversity) technology. It is administered through intravenous route.Alligator Bioscience overviewAlligator Bioscience is a pharmaceuticals and healthcare company. The company’s pipeline products include ATOR-1015, ATOR-1017 and ALG.APV-527. The ADC-1013, is a human, monospecific, agonistic, IgG1 antibody used for immunotherapy of cancer; ATOR-1015, is a bispecific immune activating antibody intended for tumor-directed immunotherapy. Its preclinical development phase products ATOR-1017 and ALG.APV-527 are antibodies for activating the co-stimulatory receptor 4-1BB, and for treating tumor-directed immunotherapy respectively. The company develops immunotherapies such as agonistic mono- and bispecific antibodies. It develops immunotherapeutic product candidates using proprietary technologies, Alligator-Gold and fragment induced diversity (FIND). Alligator Bioscience is headquartered in Lund, Sweden. For a complete picture of ALG.APV-527's drug-specific PTSR and LoA scores, buy the report here.
ALG.APV-527 is under clinical development by Alligator Bioscience and currently in Phase II for Solid Tumor.
What's Your Reaction?
